Combined F-18 NaF and F-18 FDG PET/CT for Evaluation of Malignancy

Stanford University214 enrolled

Overview

Fluorine-18 Fluorodeoxyglucose (F-18 FDG) PET/CT is established as a powerful imaging tool for cancer detection and monitoring response to therapy. Sodium Fluorine-18 (F-18) was used in the 1970s for bone scanning and can be used as a skeletal tracer in current PET/CT scanners. The combined administration of F-18 and F-18 FDG in a single PET/CT scan for cancer detection was not attempted to date. We hope to learn what is the best approach for detection of cancer and thus to improve cancer treatment.

Study Type

OBSERVATIONAL

Enrollment

214

Conditions

Neoplasms

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients older than 18-year-old, diagnosed with cancer * Patients must understand and voluntarily sign an Informed Consent form after the contents have been fully explained to them Exclusion Criteria: * Patients who cannot complete a PET/CT scan * Pregnant women * Healthy volunteers * Patients participating in other research studies The subjects will not be paid to participate in this protocol. No costs will be charged to the subjects.

Locations (5)

Stanford University School of Medicine

Stanford, California, United States

Aalborg Hospital

Aalborg, Denmark

Apollo Hospital

Chennai, India

Coimbra University Hospital

Coimbra, Portugal

Pretoria Academic Hospital

Outcomes

Primary Outcomes

Percent of patients with evidence of new lesions on combined F-18/F-18 FDG PET/CT.

Time frame: not defined

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.